MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

36.29 2.69

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

36.17

Massimo

36.42

Metriche Chiave

By Trading Economics

Entrata

33M

-48M

Vendite

-2.6M

106M

EPS

-0.45

Margine di Profitto

-45.487

Dipendenti

1,869

EBITDA

19M

-56M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+55.77% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

498M

3.9B

Apertura precedente

33.6

Chiusura precedente

36.29

Notizie sul Sentiment di mercato

By Acuity

50%

50%

115 / 375 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 lug 2025, 04:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

4 lug 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

4 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 15:57 UTC

Discorsi di Mercato

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 lug 2025, 15:49 UTC

Discorsi di Mercato

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 lug 2025, 15:49 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Received All Required Authorizations

4 lug 2025, 15:48 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 lug 2025, 15:47 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 lug 2025, 15:46 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 lug 2025, 14:30 UTC

Acquisizioni, Fusioni, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 lug 2025, 13:53 UTC

Discorsi di Mercato

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 lug 2025, 13:41 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

4 lug 2025, 13:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 lug 2025, 12:37 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 lug 2025, 12:30 UTC

Discorsi di Mercato

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 lug 2025, 12:15 UTC

Discorsi di Mercato

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 lug 2025, 12:13 UTC

Discorsi di Mercato

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 lug 2025, 12:02 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

55.77% in crescita

Previsioni per 12 mesi

Media 56.7 USD  55.77%

Alto 75 USD

Basso 38.2 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

115 / 375 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.